Wierda, W. G., Shah, N. N., Cheah, C. Y., Lewis, D., Hoffmann, M. S., Coombs, C. C., Lamanna, N., Ma, S., Jagadeesh, D., Munir, T., Wang, Y., Eyre, T. A., Rhodes, J. M., McKinney, M., Lech-Maranda, E., Tam, C. S., Jurczak, W., Izutsu, K., Alencar, A. J., … Ghia, P. (2024). Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. The Lancet Haematology, 11(9), e682–e692. https://doi.org/10.1016/s2352-3026(24)00172-8

Payne, A. S., & Manfredo Vieira, S. (2024). Bruton’s Tyrosine Kinase Inhibition in Pemphigus: An Embattled Frontier. Journal of Investigative Dermatology, 144(8), 1667–1670. https://doi.org/10.1016/j.jid.2024.03.014